Skip to main content
. Author manuscript; available in PMC: 2019 Aug 1.
Published in final edited form as: Ann Thorac Surg. 2018 Mar 23;106(2):375–381. doi: 10.1016/j.athoracsur.2018.02.049

Table 4:

Competing risks model for time to lung cancer recurrence

HR (95% CI) P-value
Age (per decade) 1.01 (1.00, 1.02) 0.230
Sex: Male (reference)
 Female 0.86 (0.68, 1.10) 0.231
Surgery: Lobectomy (reference)
 Sublobar Resection 1.39 (1.04, 1.87) 0.026
Pathologic Stage 1 (reference)
 Stage 2 1.54 (1.03, 2.30) 0.035
 Stage 3 1.70 (1.07, 2.72) 0.026
Histology: Adenocarcinoma (reference)
 Squamous 0.66 (0.49, 0.89) 0.007
 Other histology 0.97 (0.67, 1.41) 0.876

Patients with positive surgical margins were excluded for competing risks analysis